USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Triplex Pharmaceutical
Address:
9391 Grogans Mill Road
The Woodlands, TX 77380
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
Yes
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $953,849.00 14

Award List:

ANTI-HSV-1 ACTION OF TRIPLEX FORMING OLIGONUCLEOTIDES

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$49,095.00
Agency:
HHS
Principal Investigator:
Susan M Fennewald
Abstract:
The aim of this project is to test the feasibility of using triplex forming oligonucleotides as antiviral agents againstherpes simplex virus type 1. oligonucleotides have long been known to be capable of binding to duplex dna to form triple helix complexes. advances in triplex technology now allows… More

MODIFIED NUCLEOSIDES IN TRIPLEX FORMING OLIGONUCLEOTIDES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ganapathi R Revankar
Abstract:
The primary goal of this study is to chemically refine a class of sequence-specific, dna binding, triple helix-forming oligonucleotides (tfos). the unique feature of these tfos is that binding of the third strand to its duplex dna target is ph independent and is stabilized by ggc and tat triplets… More

ANTI HIV-1 ACTIVITY OF TRIPLEX FORMING OLIGNUCLEOTIDES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Joseph G Zendegui
Abstract:
Antiviral agents for the treatment for human immunodeficiency virus (hiv-1) are dearly in great need. we have synthesized and done preliminary experiments with a triple helix forming oligonucleotide designed to bind to critical regulatory regions in the proviral genome of hiv-1. preliminary data… More

IMPROVED TRIPLE HELIX FORMING OLIGONUCLEOTIDES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,998.00
Agency:
HHS
Principal Investigator:
Ross H Durland
Abstract:
Triple helix forming oligonucleotides (tfos) offer the potential to specifically modulate expression of any gene in a sequence dependent manner. at present, tfos can be designed to bind to certain targets in duplex dna, forming a localized three-stranded structure. such structures can block action… More

MODIFIED OLIGONUCLEOTIDES INTRIPLE HELIX FORMATION

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Ganapathi R Revankar
Abstract:
The primary goal of this study is to chemically refine a class of sequence-specific, dna binding, triple helix-forming oligonucleotides (tfos). the unique feature of these tfos is that binding of the third strand to its duplex dna target is ph independent and is stabilized by ggc and tat triplets… More

Enhanced Efficacy of Triplex Oligonucleotides

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Krishna Jayaraman
Abstract:
We will develop a novel class of therapeutics based on Triple-Helix Forming Oligonucleotides (TFOs). Attachment of lipophilic groups to anti-cancer and anti- HSV-2 TFOs will be examined to enhance their cellular efficacy. Specifically, cholesteryl modified TFOs that are designed to bind to the… More

Triplex Inhibition of Progesterone Receptor

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
June Santon
Abstract:
Triple helix formation between duplex DNA and oligonucleotides has been observed for over twenty years for synthetic polymers and more recently for genomic DNA. Triplex formation prevents the association of proteins with DNA including transcription factors and RNA polymerase. Triple helix formation… More

Anti-HCMV Activity of Triple Helix-Forming Oligos

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$40,000.00
Agency:
HHS
Principal Investigator:
Robert F. Rando
Abstract:
The aim is to test the feasibility of using triple helix (triplex)-forming oligonucleotides as antiviral agents against human cytomegalovirus. Oligonucleotides have long been known to be capable of binding to duplex DNA to form triple helix complexes. Advances in triplex technology now allows the… More

Oligonucleotides Inhibition of HIV-1 Integrase

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$65,956.00
Agency:
HHS
Principal Investigator:
Joshua Ojwang
Abstract:
Effective therapy for human immunodeficiency virus (HIV) infection remains elusive, partly dueto the fact that infected long lived cells provide a reservoir for the virus. Currently availableanti-retroviral agents are reverse transcriptase inhibitors. In spite of their success, these compoundshave… More

Development of a Novel Anti-HIV Oligonucleotide

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$98,800.00
Agency:
HHS
Principal Investigator:
Thomas Wallace
Abstract:
AIDS is a fatal disorder of the immune system caused by the HIV and is a widespread epidemic. The lobjective of this work is to treat human AIDS patients with a novel oligonucleotide (T30177) that haanti-HIV activity. We will perform preclinical animal pharmacology studies, including… More

Development of a Novel Cytomegalovirus Drug

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Thomas Wallace
Abstract:
Cytomegalovirus (CMV) causes severe infections in infants, organ transplant recipients and AIDS patlong term objective of this work is to treat humans who have cytomegalovirus infections with a novelspecific aims of this grant are to perform animal pharmacology studies, including efficacy,… More

Active Anti-HIV Guanosine/Thymidine Oligonucleotides

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Robert Rando
Abstract:
We will develop a new class of oligonucleotides, which fold themselves into ordered structures andmainly of deoxyguanosine and deoxythymidine (GTOs), as therapeutic antiviral agents active against HGTOs as antiviral agents represents the results of a productive investigation into the mechanism… More

Alkenylguanine Analogs--A New Class of Antiviral Agent

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Arthur Lewis
Abstract:
We will develop certain structure activity relationships with respect to a novel class of antiviralconduct preliminary experiments designed to define the mechanism of action for these drugs. Preliminestablished that certain alkenes, when attached to a guanine congener, provide potential antiviral… More

New Delivery Systems for Therapeutic Oligonucleotides

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Nilabh Chaudhary
Abstract:
Antisense and triple helix-forming oligonucleotides (TFOs) have great potential as therapeutic agenspecifically block the expression of deleterious genes. We will develop novel delivery vehicles, tointernalization and membrane permeability of oligonucleotides. These compounds are polyaminolipids… More